Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.

PLoS One · 2013 · PMC3639207 · PMID 23658636

Europe PMC DOI

hedged sentences

0.0560

closest p · 1.1× alpha

0.0700

boldest claim

The sentences

showed a trendp = 0.056so close (0.05 < p ≤ 0.1)

Response to IFN Beta Therapy The SNP rs20576 in exon 5 in TRAILR-1, which showed a trend in the original cohort (recessive model: p = 0.056, OR = 0.41), was significantly associated in the validation cohort (recessive model: p = 4.83×10 −3 , OR = 0.19) and it reached the Bonferroni level of significance in the joint analysis (recessive model: p = 8.88×10 −4 , pc = 0.048, OR = 0.30) ( Table 2 ).

also in 53,322 other papers

borderline significancep = 0.07so close (0.05 < p ≤ 0.1)

The borderline significance in the allelic comparison of responders and non-responders [p = 0.07; OR (95% CI) = 0.8 (0.62–1.03)] is due to the low minor allele frequency (MAF) of this polymorphism.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.